MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
0.4630
-0.1360
-22.70%
After Hours: 0.4700 +0.007 +1.51% 18:29 11/10 EST
OPEN
0.6500
PREV CLOSE
0.5990
HIGH
0.6750
LOW
0.4500
VOLUME
382.15K
TURNOVER
--
52 WEEK HIGH
4.340
52 WEEK LOW
0.4500
MARKET CAP
6.92M
P/E (TTM)
-0.2867
1D
5D
1M
3M
1Y
5Y
1D
Lantern Pharma announces publication of Phase 1a LP-184 data
TipRanks · 14h ago
Lantern Pharma's Stralight Therapeutics Publishes LP-184 Phase 1a GBM Data, Establishing The Recommended Dose For Expansion And A Clinically Translatable Dosing Strategy For The Planned Phase 1b/2a Trial
Benzinga · 17h ago
Weekly Report: what happened at LTRN last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at LTRN last week (1026-1030)?
Weekly Report · 11/02 09:14
Weekly Report: what happened at LTRN last week (1019-1023)?
Weekly Report · 10/26 09:14
Weekly Report: what happened at LTRN last week (1012-1016)?
Weekly Report · 10/19 09:14
Powering the AI Economy: New to The Street Show #776 Premieres Tonight on Bloomberg Television
Barchart · 10/17 11:35
Weekly Report: what happened at LTRN last week (1005-1009)?
Weekly Report · 10/12 09:15
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.